Malignant mesotheliomas are relatively rare, highly malignant tumours that arise from the mesothelial cells lining the serosal cavities of the body. The most frequent are malignant pleural mesotheliomas (MPMs) ([@bib4]), whose estimated annual incidence in Europe (15--33 cases per million inhabitants) is expected to increase further over the next 20 years because of their long period of latency ([@bib28]). The main carcinogen associated with MPMs is asbestos, and occupational exposure to it has been considered the main risk factor ([@bib38]; [@bib21]; [@bib5]); however, other potential carcinogenic agents include infection by Simian Virus 40 and radiation exposure ([@bib39]).

The median survival of patients with MPM is currently 12 months from the time of diagnosis despite treatment ([@bib37]). The European Organisation for Research and Treatment of Cancer has indicated that the main predictors of a negative prognosis are a poor performance status (PS), high white blood cell counts, male gender, a sarcomatoid subtype, anaemia, and thrombocytosis ([@bib8]), but it has been recently suggested that short survival may also be related to a high nuclear tumour grade, a high MIB-1 labelling index ([@bib6]), and high epidermal growth factor receptor (EGFR) expression in tumour cells ([@bib30]).

There is no standard of care for MPM, but systemic chemotherapy is the only possible treatment option for most patients at the time of diagnosis. It has been found that pemetrexed combined with cisplatin is more effective than platinum alone in terms of overall survival (12.1 *vs* 9.3 months), time to progression (5.7 *vs* 3.9 months), and objective responses (41.3% *vs* 16.7% of tumour shrinkage) ([@bib37]), but, as most patients progress during or shortly after these first-line treatments, there is a clear need to develop more effective antitumour agents.

Epidermal growth factor receptor is a receptor tyrosine kinase that is overexpressed in 60--70% of MPM tissue specimens (mainly of the epithelial subtype), but not in the normal mesothelium ([@bib9]; [@bib10]; [@bib25]). Exposure to asbestos fibres causes EGFR aggregation, and the subsequent autophosphorylation and activation of EGFR activates both the RAS/RAF/MAPK pathway (which induces cell proliferation, metastasis, and invasion) ([@bib26]) and the PI3KCA/AKT/mTOR pathway, which leads to the inhibition of apoptosis ([@bib34]). Consequently, inhibiting EGFR pathways should have an antitumoral effect. Two classes of EGFR inhibitors have been developed for cancer therapy: tyrosine kinase inhibitors (TKIs), which block EGFR autophosphorylation by competing with ATP binding, and anti-EGFR monoclonal antibodies (mABs), which compete with the ligand binding the extracellular domain of EGFR. It has been reported that mutation analysis of the *EGFR* gene and of some of its downstream signal-transduction proteins predicts the response of lung adenocarcinomas to TKIs ([@bib32]) and the response of colorectal cancer to anti-EGFR mABs (cetuximab, panitumumab) ([@bib19]).

Preclinical studies have shown that EGFR TKIs are highly efficacious ([@bib3]), but two phase II studies of gefitinib and erlotinib used alone to treat malignant pleural and peritoneal mesotheliomas failed to demonstrate their clinical efficacy, although it needs to be pointed out that the patients in both trials were not selected on the basis of any molecular criteria ([@bib18]; [@bib16]). One recent study has shown that cetuximab effectively blocks the growth of MPM cells in cell cultures and mouse models ([@bib20]) and, as in the case of colorectal cancer and lung adenocarcinomas, the potential efficacy of these TKIs in MPM may depend on the mutation status of *EGFR* gene and its downstream effectors ([@bib22]; [@bib29]).

To the best of our knowledge, only a few low-powered studies have investigated the presence and frequency of *EGFR* gene mutations in MPM ([@bib7]; [@bib13]), and none has searched for mutations in the *KRAS*, *BRAF*, and *PI3KCA* downstream effectors. We searched a large series of histological MPM samples for mutations in *EGFR* gene and its main downstream signalling effectors to evaluate their frequency and possible prognostic significance, and their possible use as predictors of the response of MPMs to targeted therapies.

Materials and methods
=====================

Patients and samples
--------------------

The study involved 77 consecutive MPM patients admitted to the Thoracic Unit of the University Hospital of Novara between January 2008 and December 2010, all of whom were diagnosed as having MPM on the basis of multiple pleural biopsies taken by means of video-assisted thoracoscopy. The tumour samples were immediately fixed in formalin for 24 h, embedded in paraffin, and routinely processed for histology and immunohistochemistry, and the diagnosis of MPM was based on standard histological and immunohistochemical criteria, including positivity to calretinin, vimentin, and cytokeratins 5 and 6, and negativity to carcinoembryonic antigen, thyroid transcription factor 1, and Ber Epy 4. The MPMs were classified on the basis of the WHO classification of pleural tumours ([@bib35]), and clinically and pathologically staged on the basis of the TNM staging system ([@bib33]). The patients\' PS at the time of diagnosis was graded using the Eastern Cooperative Oncology Group (ECOG) scale ([@bib24]), and the patients with a PS of 0--2 underwent therapeutic protocols indicated by the referring oncologist.

Haematoxylin/eosin-stained slides of the pleural biopsies and corresponding formalin-fixed, paraffin-embedded blocks were reviewed by a pathologist (RB) to select the area with \>50% of tumour cells.

DNA extraction
--------------

The tumoral areas of the formalin-fixed, paraffin-embedded sections were macrodissected manually, and then five 5-*μ*m-thick sections were prepared and collected in a 1.5 ml tube. Genomic DNA was extracted using EDTA-SDS/proteinase K followed by phenol--chloroform, and resuspended with 30 *μ*l of DEPC-treated and RNAse-free water (Promega, Madison, WI, USA).

Mutational analysis
-------------------

### *Epidermal growth factor receptor* gene

All of the samples were analysed using the TheraScreen EGFR29 Mutation Kit (Qiagen, Manchester, UK), which combines the two technologies of ARMS and Scorpion chemistry to detect mutations in a real-time polymerase chain reaction (PCR). This kit allows the detection of in-frame deletions on exon 19, insertions on exon 20, and G719X, S768I, T790M, L858R, and L861Q mutations against a background of WT genomic DNA with a sensitivity of 1%. Starting from 2 *μ*l of genomic DNA, the analyses were made in accordance with the manufacturer\'s instruction using RotorGene Q (Qiagen), and the results were interpreted following the datasheet.

To determine the presence of other less common mutations, the samples underwent further PCRs to amplify the whole sequence of exons 18--21 of the *EGFR* gene as described previously by [@bib27]. [Table 1](#tbl1){ref-type="table"} shows the primers and PCR conditions.

### *KRAS* gene

The *KRAS* gene was analysed by means of a mutant-enriched PCR (ME-PCR) to detect the hotspots in codons 12 and 13 of exon 2 that include more than 95% of the known gene mutations. The ME-PCR consisted of two amplification steps (seminested PCR) in which artificial restriction sites were introduced into the wild-type amplicon using mismatched primers ([Table 1](#tbl1){ref-type="table"}). The restriction sites (*Bst*NI for codon 12 and *Bgl*I for codon 13) introduced during the first PCR step were localised immediately next to the KRAS codon in the analysis to distinguish wild-type and mutant sequences. The wild-type amplicons were then digested by *Bst*NI or *Bgl*I restriction enzymes, and the mutant products were enriched for a second round of amplification. The ME-PCR and digestion conditions have been described previously ([@bib23]). Mutant-enriched PCR has a sensitivity of up to 0.01%. All of the samples underwent automated sequencing by using an ABI PRISM 3130 (Applied Biosystems, Foster City; CA, USA) and reverse primers.

### *BRAF* gene

Exon 15 of the *BRAF* gene (which contains the hotspot codon 600, where more than 90% of gene mutations occur) was analysed by means of direct sequencing in accordance with previously published protocols ([@bib11]), starting from 50 ng of genomic DNA. The primers and PCR conditions are shown in [Table 1](#tbl1){ref-type="table"}.

### *PI3KCA* gene

The analysis of the *PIK3CA* gene was concentrated on exons 9 and 20, which include all of the hotspot codons, using previously published protocols ([@bib31]). The primers and PCR conditions are shown in [Table 1](#tbl1){ref-type="table"}.

### Sequence analysis

All of the PCR products and KRAS second enzymatic digestions were analysed by means of 3% agarose gel electrophoresis, and then purified using NucleoSpin Gel and the PCR clean-up kit (Macherey-Nagel, Düren, Germany). The sequence of each gene was analysed using an ABIPrism 3130 Genetic Analyzer (Applied Biosystems), and all of the mutated cases were confirmed two times starting from independent PCR reactions.

Statistical analysis
--------------------

This examined the correlations between the presence of gene mutations and other demographic, clinical and pathological variables. The associations between categorical variables were determined using the *χ*^2^ or Fisher\'s exact test. The statistical differences of the average values were tested using a Student\'s *t*-test and analysis of variance, followed by Bonferroni\'s test.

The impact of the different variables on long-term outcomes was analysed using the Kaplan--Meier method of analysing disease-specific survival (DSS); the survival data were compared using the log-rank test.

*P*-values of \<0.05, with a 95% confidence interval, were considered statistically significant.

Results
=======

In all, 57 patients were male (74%) and 20 were female (26%); their average age at the time of diagnosis was 68 years (range 43--90, median 64.5 years). Of these, 50 patients (64.9%) had previously been exposed to asbestos at work. Histological examination showed that 59 MPMs (77%) were epithelioid, 10 (13%) biphasic, and 8 (10.4%) sarcomatoid. In total, 41 patients had stage II tumours, 30 stage III tumours, and 6 stage IV tumours. Eastern Cooperative Oncology Group PS was 0--2 in 68 patients, and \>2 in nine patients. In all, 41 patients were treated with platinum plus pemetrexed and 22 with platinum alone; 14 received no treatment because their PS was \>2 or because they refused.

Follow-up data were collected from 74 patients (three were lost to follow-up). In all, 15 patients were still alive at June 2012 with a median follow-up of 24.5 months (range 14--39 months). The median DSS of the cohort as a whole was 12.5 months (range 1--39 months).

Mutation analysis
-----------------

Mutations in the EGFR downstream pathway were identified in nine patients (12%): five in the *KRAS* gene, three in the *BRAF* gene, and one in the *PIK3CA* gene. No mutations were detected in the *EGFR* gene by direct sequencing or the Scorpions-ARMS assay, even though the latter has a sensitivity of 1% (*vs* the 10--20% of direct sequencing).

### *KRAS* and *BRAF* gene mutational profiling

The *KRAS* gene was successfully amplified in all of the samples, five of which showed mutations: two patients had the GGT→GtT point mutation in codon 12 leading to a glycine-to-valine amino-acid substitution (G12V); two had the GGC→GaC point mutation in codon 13 leading to a glycine-to-aspartic acid substitution (G13D); and one had the rare GGC→aGC mutation in codon 13 leading to a glycine-to-serine substitution (G13S). As shown in [Table 2](#tbl2){ref-type="table"}, three of the five mutations occurred in patients with epithelioid MPMs (G12V, G13D, and G13S), one in a patient with a biphasic MPM (G13D), and one in a patient with a sarcomatoid subtype (G12V). All five patients with *KRAS* mutations reported previous occupational asbestos exposure.

The *BRAF* gene mutational analysis showed the classical valine-to-glutamic amino-acid substitution in codon 600 (V600E) in three patients: two with epithelioid MPMs and one with a biphasic tumour ([Table 2](#tbl2){ref-type="table"}). None of them reported previous occupational asbestos exposure.

### *PI3KCA* gene mutational profiling

The DNA of exons 9 and 20 of the *PIK3CA* gene was successfully amplified from 75 of the 77 specimens. A point mutation was detected in only one case: it occurred in exon 20, and led to a methionine-to-isoleucine substitution in position 1040 (M1040I). The patient had a biphasic mesothelioma and no previous occupational asbestos exposure ([Table 2](#tbl2){ref-type="table"}).

Statistical analysis
--------------------

The correlations between the presence/absence of gene mutations and demographic, clinical, and pathologic features (gender, age, occupational asbestos exposure, history of previous cancer, histological type, ECOG PS, treatment) were investigated, without finding any significant differences ([Table 3](#tbl3){ref-type="table"}).

The Kaplan--Meier analysis of the influence of some variables on long-term outcomes revealed no difference in DSS between the patients with and without gene mutations (*P*=0.552). Moreover, separate evaluation of the patients with *KRAS* and *BRAF* mutations did not indicate any advantage in terms of DSS (*P*=0.363 and 0.752) and, within the mutated group, no mutation significantly correlated with DSS (*KRAS*, *P*=0.363; *BRAF*, *P*=0.187).

Interestingly, the patients with *KRAS* gene mutations reported occupational asbestos exposure, whereas those with *BRAF* and *PI3KCA* gene mutations did not. When the DSS of the patients with reported asbestos exposure was considered, the five *KRAS* gene-mutated patients had a worse prognosis than those with wild-type *KRAS* (*n*=42), although the difference was not statistically significant (mean survival, 9.20±6.91 *vs* 15.6±10.39 months; *P*=0.188) ([Figure 1A](#fig1){ref-type="fig"}). On the contrary, the DSS of the patients without reported occupational asbestos exposure was better in the *BRAF* gene-mutated patients (*n*=3) than in those without *BRAF* mutations (*n*=22), although, once again, the difference was not statistically significant (mean survival, 20.33±12.06 *vs* 12.1±8.37 months; *P*=0.140) ([Figure 1B](#fig1){ref-type="fig"}).

Discussion
==========

As EGFR is involved in the carcinogenesis of MPM, it is possible that EGFR-targeted therapies may be efficacious in MPM patients ([@bib3]). Epidermal growth factor receptor TKI inhibitors, such as gefitinib and erlotinib, inhibit MPM cell migration and proliferation, enhance the response to radiation of human MPM cell lines, and reduce motility and invasion in MPM cell lines ([@bib20]). However, the promising results obtained in *in vitro* studies were not reproduced in two phase II trials involving patients with pleural and peritoneal mesotheliomas, although it should be noted that neither study evaluated the mutation status of the *EGFR* gene and its downstream signalling transduction pathway ([@bib18]; [@bib16]). As in the case of colorectal cancer and lung adenocarcinoma, this lack of molecular selection could explain the therapeutic failure.

The few studies that have sought mutations in the tyrosine kinase domain of the *EGFR* gene in patients with malignant mesotheliomas involved small populations and used a relatively insensitive method (the direct sequencing of exons 18--21) ([@bib7]; [@bib36]; [@bib13]). The primary objective of our study was to look for *EGFR* gene mutations in a larger series of patients (*n*=77) using two molecular methods: all of the cases were first screened using Scorpion-ARMS technology, which is capable of detecting 1% of mutated cells against a 99% background of wild-type cells, followed by direct sequencing to find rarer mutations or mutations that cannot be detected using the first method. However, despite this, we did not find any mutations in the TK domain of *EGFR*: in addition to confirming previous findings ([@bib7]; [@bib36]), this also indicates that, unlike in the case of lung adenocarcinomas, mutations cannot be detected even when real-time PCR is used to increase sensitivity ([@bib2]).

On the contrary, [@bib13] have recently studied 38 patients and found *EGFR* missense mutations in exons 18 (*n*=1), 20 (*n*=3), and 21 (*n*=1) in six (16%) patients with pleural (*n*=3) or peritoneal mesotheliomas (*n*=3). Epidermal growth factor receptor gene mutations have been previously found in peritoneal mesotheliomas ([@bib14], [@bib15]), but this is the only published report of *EGFR* gene mutations in MPM. However, the study involved Japanese patients, who are characterised by more frequent *EGFR* gene mutations in lung adenocarcinoma than Western patients ([@bib12]). Furthermore, some of the detected mutations had never been reported before, and their biological and clinical significance is still unknown.

An alternative method of blocking EGFR is to use mABs, which may be extremely useful as it has been demonstrated that MPM patients show *EGFR* gene amplification ([@bib9]; [@bib10]; [@bib25]). No published studies have assessed the *in vivo* effects of anti-EGFR mAbs on MPMs, although one recent study has found that cetuximab is highly efficacious in cultured MPM cell lines ([@bib20]). It has been demonstrated that mutations in EGFR downstream pathways can affect the efficacy of EGFR mABs in other tumours such as colorectal adenocarcinoma ([@bib19]), and we found nine patients (11.7%) with missense mutations involving the *KRAS* (*n*=5), *BRAF* (*n*=3), and *PIK3CA* genes (*n*=1). Few other studies have separately investigated the presence of mutations in *KRAS*, *BRAF*, and *PIK3CA* genes in MPM samples and mesothelioma cell lines without success (see review by [@bib1]), but, to the best of our knowledge, ours is the first to investigate these alterations systematically in a large series of MPM patients.

Various reasons may explain these discrepant results. We screened a large number of samples (*n*=77), whereas the other studies were based on smaller series and may have underestimated the real frequency of such mutations. Furthermore, we analysed *KRAS* gene mutations using an ME-PCR technology whose sensitivity is 0.1% ([@bib23]), and so it is possible that the percentage of *KRAS* gene-mutated cells is very low in MPM and that more widely used sequencing methods are unable to detect small clones.

Our findings show that, although infrequent, mutations in EGFR downstream pathways can be found in MPMs, thus supporting the hypothesis that EGFR mABs may be clinically effective in the majority of patients. On the other hand, patients with a molecular profile indicating putative resistance to EGFR mABs (because of the presence of *KRAS* or *BRAF* or *PIK3CA* mutations) may be directed towards new targeted therapies. One recent study has shown that vemurafenib is promising not only in patients with metastatic melanoma but also in patients with non-small-cell lung cancer carrying a *BRAF* mutation ([@bib17]), and selumetinib and BYL-719, which target *KRAS* and *PIK3CA* mutations, are currently being evaluated in several clinical trials (<http://ctmagnifier.org/>). Our data therefore underline the importance of the molecular characterisation of patients with MPM.

The clinical implications of the gene mutations detected in our study are not clear. DSS was no different in the patients with or without gene mutations (whether analysed together or separately). Interestingly, all of the patients with *KRAS* gene mutations reported occupational asbestos exposure, but none of those with *BRAF* or *PIK3CA* gene mutations. Comparison of mean DSS in the *KRAS* and *BRAF* gene-mutated patients *vs* wild-type patients previously exposed to asbestos or not, showed that the *KRAS* gene-mutated patients (*n*=5) tended to have a worse prognosis than the wild-type patients (9.20±6.91 *vs* 15.6±10.39 months), and the *BRAF* gene-mutated patients (*n*=3) tended to have a better prognosis (20.33±12.06 *vs* 12.1±8.37 months). However, the differences were not statistically significant and our findings need to be confirmed in larger series of MPM patients.

In conclusion, our extensive molecular characterisation of EGFR pathways may explain the failure of TKI administration and may open up the possibility of developing new targeted therapies.
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###### Sequences of primers and PCR reaction protocol

  **Gene**                    **Primer name**      **Sequence**                                            **Cycle**                                                                                              **Length**
  --------------------------- -------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------
  *KRAS codon* *12 (outer)*   3F                   5′-ACTGAATATAAACTTGTGGTAGTTGGACCT--3′                   95 °C × 10 min; (95 °C × 30 s, 50 °C × 1 min, 72 °C × 1 min) × 20 cycles; 72 °C × 3 min                143
                              10B                  5′-ACTCATGAAAATGGTCAGAGAAACCTTTAT-3′                                                                                                                            
  *KRAS codon 13 (outer)*     9F                   5′-ACTGAATATAAACTTGTGGTAGTTGGCCCTGGT-3′                 95 °C × 10 min; (95 °C × 30 s, 54 °C × 1 min, 72 °C × 1 min) × 20 cycles; 72 °C × 3 min                113
                              10B                  5′-ACTCATGAAAATGGTCAGAGAAACCTTTAT-3′                                                                                                                            
  *KRAS codon 12 (inner)*     3F                   5′-ACTGAATATAAACTTGTGGTAGTTGGACCT-3′                    95 °C × 10 min; (95 °C × 30 s, 54 °C × 1 min, 72 °C × 1 min) × 45 cycles; 72 °C × 3 min                143
                              14B                  5′-TCAAAGAATGGTCCTGGACC-3′                                                                                                                                      
  *KRAS codon 13 (inner)*     9F                   5′-ACTGAATATAAACTTGTGGTAGTTGGCCCTGGT-3′                                                                                                                        113
                              4B                   5′-TCAAAGAATGGTCCTGCACC-3′                                                                                                                                      
  *EGFR exon 18*              EGFR18F              5′-TCCAGCATGGTGAGGGCTGAG-3′                             50 °C × 2 min; 95 °C × 10 min; (95 °C × 40 s, 58 °C × 40 s, 72 °C × 35 s) × 40 cycles; 72 °C × 3 min   242
                              EGFR18R              5′-GGCTCCCCACCAGACCATG-3′                                                                                                                                       
  *EGFR exon 19*              EGFR19F              5′-TGGGCAGCATGTGGCACCATC-3′                                                                                                                                    217
                              EGFR19R              5′-AGGTGGGCCTGAGGTTCAG-3′                                                                                                                                       
  *EGFR exon 20*              EGFR20F              5′-CCTCCTTCTGGCCACCATGCG-3′                                                                                                                                    296
                              EGFR20R              5′-CATGTGAGGATCCTGGCTCC-3′                                                                                                                                      
  *EGFR exon 21*              EGFR21F              5′-CCTCACAGCAGGGTCTTCTC-3′                                                                                                                                     229
                              EGFR21R              5′-CCTGGTGTCAGGAAAATGCT-3′                                                                                                                                      
  *BRAF exon 15*              BRAF15F              5′-TCATAATGCTTGCTCTGATAGGA-3′                           95°C × 10 min; (95 °C × 15 s, 52 °C × 30 s, 72 °C × 30 s) × 45 cycles; 72 °C × 3 min                   224
                              BRAF15R              5′-GGCCAAAAATTTAATCAGTGGA-3′                                                                                                                                    
  *PIK3CA exon 9*             PIK3CA9F             5′-GGGAAAAATATGACAAAGAAAGC-3′                           95 °C × 10 min; (95 °C × 35 s,                                                                         251
                              PIK3CA9R             5′-CTGAGATCAGCCAAATTCAGTT-3′                            56 °C × 30 s, 72 °C × 30 s) × 40 cycles; 72 °C × 10 min                                                 
  *PIK3CA exon 20*            PIK3CA20FPIK3CA20R   5′-CTCAATGATGCTTGGCTCTG-3′5′-TGGAATCCAGAGTGAGCTTTC-3′                                                                                                          241

###### Characteristics of patients with gene mutations

  **Patient**      **Gene**     **Amino-acid substitution**  **Gender**   **Age**   **Histotype**    **Asbestos exposure**  **DSS**
  ------------- -------------- ----------------------------- ------------ --------- --------------- ----------------------- ---------
  1               ***KRAS***               G12V              Male         81        Sarcomatoid               Yes           4
  2                                        G12V              Male         55        Epithelioid               Yes           14
  3                                        G13D              Male         82        Epithelioid               Yes           4
  4                                        G13S              Male         60        Epithelioid               Yes           5
  5                                        G13D              Male         77        Biphasic                  Yes           19
  6               ***BRAF***               V600E             Female       51        Epithelioid              None           9
  7                                        V600E             Male         57        Biphasic                 None           19
  8                                        V600E             Male         73        Epithelioid              None           33
  9              ***PIK3CA***             M1040I             Male         68        Biphasic                 None           7

Abbreviation: DSS=disease-specific survival.

###### Statistical correlation between demographic, clinical, pathological data, and gene mutations

                              **Wild type (*****n*****=68)**   **Mutations (*****n*****=9)**  ***P*****-value**
  -------------------------- -------------------------------- ------------------------------- -------------------
  Age, mean±s.d. (years)                  66±21                            67±12              0.89
  Gender (male proportion)                49/68                             8/9               0.491
  Previous cancer                          5/68                             2/9               0.385
  Asbestos exposure                       44/68                             6/9               0.799
  **Histological subtype**                                                                    
  Epithelial                              54/68                             5/9               0.241
  Biphasic                                 7/68                             3/9               0.135
  Sarcomatoid                              7/68                             1/9               0.623
  **ECOG score**                                                                              
  0--2                                    60/68                             8/9               0.892
  \>2                                      8/68                             1/9               0.617
  **Clinical stage**                                                                          
  II                                      37/68                             4/9               0.689
  III--IV                                 31/68                             5/9               0.576
  **Treatment type**                                                                          
  None                                    13/68                             1/9               0.623
  Platinum                                19/68                             3/9               0.876
  Platinum+pemetrexed                     36/68                             5/9               0.776

Abbreviations: ECOG=Eastern Cooperative Oncology Group; s.d.=standard deviation.
